Article Sidebar

PDF
Date Published: 26/04/2024
Abstract Views: 39
Views PDF: 17
DOI: https://doi.org/10.56535/jmpm.v49i4.573
Issue
Vol. 49 No. 4 (2024): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 4 - 2024
Section
Articles
How to Cite
Duong, Q. H., Le, Q. N., & Nguyen, X. K. (2024). STUDY ON STAT6 rs324015 POLYMORPHISM IN HEPATITIS B VIRUS-RELATED HEPATOCELLULAR CARCINOMA PATIENTS. Journal of Military Pharmaco-medicine, 49(4), 33-42. https://doi.org/10.56535/jmpm.v49i4.573

STUDY ON STAT6 rs324015 POLYMORPHISM IN HEPATITIS B VIRUS-RELATED HEPATOCELLULAR CARCINOMA PATIENTS

Duong Quang Huy1, , Quang Nhut Le1,2, Xuan Kien Nguyen1
1 Vietnam Military Medical University
2 Tay Do University

Main Article Content

Abstract

Objectives: To determine the genotype frequency of the STAT6 rs324015 polymorphism and its association with cancer risk in hepatitis B virus (HBV) -related hepatocellular carcinoma (HCC) patients. Methods: A cross-sectional descriptive study on 118 HBV-related HCC patients, compared to 86 HBV-related cirrhosis patients and 195 healthy people at 108 Military Central Hospital, Military Hospital 103, and Can Tho General Hospital from July 2017 to August 2020. Polymorphism analysis of the STAT6 rs324015 gene was conducted from peripheral blood samples of subjects using the Sanger sequencing method at Apical Scientific Sequencing Company (Malaysia). Results: The AG/GA heterozygous genotype of the STAT6 rs324015 polymorphism accounted for the highest rate in HCC patients at 51.7%, higher than the corresponding index in the cirrhosis group at 39.5%, and healthy people (48.2%); the GG genotype was the highest in cirrhosis patients (40.7%), the difference was not statistically significant, p > 0.05. Conclusion: STAT6 rs324015 polymorphism is not associated with cancer risk in patients with HBV-related HCC.

Article Details

Keywords

STAT6 gene polymorphism, Hepatocellular carcinoma (HCC)

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209-249.
2. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018; 68(2):723-750.
3. Thomas SJ, Snowden JA, Zeidler MP, et al. The role of JAK/STAT signaling in the pathogenesis, prognosis, and treatment of solid tumours. Br. J. Cancer. 2015; 113(3):365-371.
4. Alqahtani A, Khan Z, Alloghbi A, et al. Hepatocellular carcinoma: Molecular mechanisms and targeted therapies. Medicine. 2019; 55(9): 526-547.
5. Dong Z, Chen Y, Yang C et al. STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma. OncoTargets and Therapy. 2019; 12:7175-7191.
6. Duetsch G, Illig T, Loesgen S, et al. STAT6 as an asthma candidate gene: Polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study. Hum Mol Genet. 2002; 11(6):613-621.
7. Karpathiou G, Papoudou-Bai A, Ferrand E, et al. STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology. Pathol Res Pract. 2021; 223:1-8.
8. Bộ Y tế Hướng dẫn chẩn đoán và điều trị ung thư tế bào gan nguyên phát. Ban hành kèm theo Quyết định số 5250/QĐ-BYT ngày 28 tháng 12 năm 2012 của Bộ trưởng Bộ Y tế. 2012.
9. Phan Thị Hiền Lương. Nghiên cứu đa hình gen TNF-α-308 và TGF-β1-509 ở bệnh nhân ung thư biểu mô tế bào gan có HBsAg dương tính. Luận án Tiến sĩ Y học. Học viện Quân y. 2020.
10. Ruan Z, Zhao Y, Yan L, et al. Single nucleotide polymorphisms in IL-4Ra, IL-13, and STAT6 genes occur in brain glioma. Front Biosci (Elite Ed). 2011; 3:33-45.
11. Dai L, Zhang D, Qian Y, et al. STAT6 rs324015 Gene Polymorphism increases ulcerative colitis risk: A case-control study. Pharmacogenomics and Personalized Medicine. 2021; 14:101-107.
12. Qian X, Gao Y, Ye X, et al. Association of STAT6 variants with asthma risk: A systematic review and meta-analysis. Human Immunology. 2014; 75(8):847-853.